non-small-cell-lung-cancer

Documents about non-small-cell-lung-cancer

• Foundation and Clinical About the Expression of PD-1 in Peripheral Blood T Lymphocytes#238131ClinicalTrials.gov
• A Study of SBRT Combined With Puterizumab in Intrapulmonary Metastasis From NSCLC#325288ClinicalTrials.gov
• 68Ga-grazytracer PET/CT for Early Assessment of Response to Neoadjuvant Immunotherapy in Resectable NSCLC#411396ClinicalTrials.gov
• Multi-Omics Testing for Immunotherapy Efficacy Evaluation (MOTIVATION)#411407ClinicalTrials.gov
• Neoadjuvant Nivolumab Plus Ipilimumab in Resectable NSCLC (GALAXY 3)#414502ClinicalTrials.gov
• PET/CT Radiogenomic Mutation Prediction in Non-Small Cell Lung Cancer Using Multi-Label Learning#441800arXiv CS
• Sequential Use of Low-dose Sunitinib With Chemotherapy in Advanced NSCLC After Failure of Conventional Regimen#807022ClinicalTrials.gov
• Efficacy and Safety of Pembrolizumab (MK-3475) With Lenvatinib (E7080/MK-7902) vs. Docetaxel in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) and Progressive Disease (PD) After Platinum Doublet Chemotherapy and Immunotherapy (MK-7902-008/E7080-G000-316/LEAP-008)#208463ClinicalTrials.gov
• Comparison of the Effect of Surgical Resection Based on Lesion Extent Before and After Neoadjuvant Therapy in Patients With Stage II-IIIB Non-Small Cell Lung Cancer: A Single-Center, Real-World, Open-Label Study#474747ClinicalTrials.gov
• A Study of Nivolumab + Chemotherapy or Nivolumab + Ipilimumab Versus Chemotherapy in Non-Small Cell Lung Cancer (NSCLC) Participants With Epidermal Growth Factor Receptor (EGFR) Mutation Who Failed 1L or 2L EGFR Tyrosine Kinase Inhibitor (TKI) Therapy#834767ClinicalTrials.gov
• Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing#125827ClinicalTrials.gov
• Study of ARRY-614 Plus Either Nivolumab or Nivolumab+Ipilimumab#369832ClinicalTrials.gov
• Role of Cancer-associated Fibroblast, MDSCs and Immune Cell Interplays in the Resistance of Non-small Cell Lung Cancer to Anti-PD1/PD-L1 Therapies#840246ClinicalTrials.gov
• A Single-Dose Pilot Study of Radiolabeled Amatuximab (MORAb-009) in Mesothelin Over Expressing Cancers#833788ClinicalTrials.gov
• A Study of Tarceva vs. Avastin+Tarceva for Advanced NSCLC With EGFR m(+)#835462ClinicalTrials.gov
• Study on the Mechanism of ADC Drug Evaluation Based on Immune Co-culture of Lung Cancer Organoids#303746ClinicalTrials.gov
• Study of TNG260 and an Anti-PD Antibody in STK11 Mutated Solid Tumors#826193ClinicalTrials.gov
• PET Quantitative Assessments of Solid Tumor Response to Immune Checkpoint Blockade Therapy#356479ClinicalTrials.gov
• Anlotinib Plus Chemotherapy for Patients With Advanced Non-small Cell Lung Cancer#838319ClinicalTrials.gov
• Study of 18F-Fluoro-PEG6-IPQA#805346ClinicalTrials.gov
• Real-World Effectiveness of Afatinib (Gilotrif) Following Immunotherapy in the Treatment of Metastatic, Squamous Cell Carcinoma of the Lung: A Multi-Site Retrospective Chart Review Study in the U.S.#249611ClinicalTrials.gov
• Vaccine Therapy and GM-CSF in Treating Patients With Acute Myeloid Leukemia, Myelodysplastic Syndromes, Non-Small Cell Lung Cancer, or Mesothelioma#451527ClinicalTrials.gov
• Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV#426781ClinicalTrials.gov
• Impact of Dysbiosis-inducing Drugs on Effectivity of Immune Checkpoint Inhibitor in Non-small Cell Lung Cancer Patients#28340ClinicalTrials.gov
• Hypofractionated Versus Conventional Chemoradiotherapy Followed by Consolidative Immunotherapy in Locally Advanced NSCLC#67888ClinicalTrials.gov
• Treatment and Biomarker Testing Patterns,Treatment Outcomes in a/m NSCLC With and Without Actionable Genomic Alterations#154671ClinicalTrials.gov
• OSE2101 Versus Chemotherapy in HLA-A2 Positive Patients With Advanced NSCLC After Immune Checkpoint Inhibitor Failure#226273ClinicalTrials.gov
• A fusion-based multiomics classification approach for enhanced gene discovery in non-small cell lung cancer.#266986NCBI PubMed Central
• Synthesis of novel artesunate derivatives and their in vitro activity against non-small cell lung cancer cells#274423IBISS
• A rationale for surgical debulking to improve anti-PD1 therapy outcome in non small cell lung cancer#308334HAL (France)
• Safety, Efficacy and Pharmacokinetics of ALD518 in Patients With Non-Small Cell Lung Cancer-related Fatigue and Cachexia#363598ClinicalTrials.gov
• ICI Rechallenge for Advanced NSCLC With Long-Term Response to First-Line ICI#377427ClinicalTrials.gov
• Mycoplasma infection drives EGFR-TKI resistance through convergent transcriptomic reprogramming in non-small cell lung cancer.#442884NCBI PubMed Central
• Histological specificity of alterations and expression of KIT and KITLG in non-small cell lung carcinoma.#456927Lund University Publications
• Radiation and Immune Checkpoints Blockade in Metastatic NSCLC (BMS # CA209-632)#474756ClinicalTrials.gov
• Observational Retro-prospective Study on PD1/PDL1 Inhibitors Treatment Duration in Patients With NSCLC#628532ClinicalTrials.gov
• Study to Assess the Efficacy and Safety of Adjuvant Osimertinib in NSCLC With Uncommon EGFRm#801111ClinicalTrials.gov
• Hypofractionated Radiotherapy Followed by Hypo-boost for Local Advanced NSCLC#831601ClinicalTrials.gov
• A Phase 2 Clinical Study of Combination Therapy With ABSK043 and Glecirasib#832239ClinicalTrials.gov
• Neoadjuvant Chemo-immunotherapy for Stage III PD-L1 Positive Non-Small Cell Lung Cancer (NSCLC)#835741ClinicalTrials.gov
• Neoadjuvant LDRT Combined With Durvalumab in Potentially Resectable Stage III NSCLC#836680ClinicalTrials.gov
• A Study of MDX-1106 in Patients With Selected Refractory or Relapsed Malignancies#180380ClinicalTrials.gov
• A Multi-Center Study of Ibrutinib in Combination With MEDI4736 in Subjects With Relapsed or Refractory Solid Tumors#481742ClinicalTrials.gov
• Consensus definition of stage III non-small-cell lung cancer technical resectability to standardise inclusion criteria for clinical trials: a multisocietal EORTC-Lung Cancer Group collaboration#288214HAL (France)
• Rivaroxaban Sotorasib Interaction Study#802006ClinicalTrials.gov
• LUX-Lung 8: A Phase III Trial of Afatinib (BIBW 2992) Versus Erlotinib for the Treatment of Squamous Cell Lung Cancer After at Least One Prior Platinum Based Chemotherapy#835566ClinicalTrials.gov
• Study to Test the Safety and Tolerability of PF-07257876 in Participants With Selected Advanced Tumors.#208451ClinicalTrials.gov
• Evaluation of [18F]AlF-NOTA-PCP2 PET/CT for PD-L1 Detection in Malignant Tumors#448280ClinicalTrials.gov
• Efficacy and Safety of Concurrent Chemoradiotherapy With Oral Vinorelbine in Patients With Non-small Cell Lung Cancer#272330ClinicalTrials.gov
• A Study of AB801 Monotherapy and Combination Therapy in Participants With Advanced Malignancies#837145ClinicalTrials.gov